pf-06263507
mAbexperimentalADC
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2013 (NCT01891669)
Timeline
2010s
- Jan 1, 2013
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Trophoblast glycoproteinBINDING AGENT
Trophoblast glycoprotein binding agent
- Trophoblast glycoproteinINHIBITOR
TPBG inhibitor
- TubulinINHIBITOR
Tubulin inhibitor
Beta tubulin vinca binding domain
- Tubulin beta-4B chain (TUBB4B) ↗
- Tubulin beta-1 chain (TUBB1) ↗
- Tubulin alpha-3C chain (TUBA3C) ↗
- Tubulin alpha-4A chain (TUBA4A) ↗
- Tubulin beta-3 chain (TUBB3) ↗
- Tubulin alpha-1A chain (TUBA1A) ↗
- Tubulin beta-4A chain (TUBB4A) ↗
- Tubulin beta-8 chain (TUBB8) ↗
- Tubulin beta chain (TUBB) ↗
- Tubulin alpha-1B chain (TUBA1B) ↗
- Tubulin alpha-1C chain (TUBA1C) ↗
- Tubulin alpha-3E chain (TUBA3E) ↗
- Tubulin beta-2A chain (TUBB2A) ↗
- Tubulin beta-2B chain (TUBB2B) ↗
- Tubulin beta-6 chain (TUBB6) ↗
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
- Payload
- Monomethylauristatin F
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297804 ↗
Also known as
- pf-06263507
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01891669 | Phase 1 | Aug 1, 2013 | Pfizer |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 1 | 1 | 1 | 2013 |
1 organizations
Page 1 / 1